Roland Buelow

Open Monoclonal Technology, Inc. engages in the genetic engineering of animals for discovery of human therapeutic antibodies. The firm’s transgenic animal platforms include OmniRat, industry’s first human monoclonal antibody technology based on rats; OmniMouse, a transgenic mouse that complements OmniRat and expands epitope coverage and; OmniFlic, the first engineered rat with a fixed light chain for development of bispecific, fully human antibodies. The company was founded in by Roland Buelow 2007 and is headquartered in San Diego, CA.

Medikine, Inc. is a privately held biopharmaceutical company located in an undisclosed location. The American company's mission is to transform the discovery of oncology, autoimmune disorder, and infectious disease therapeutics by employing a versatile drug discovery platform that generates modular "peptikines." These peptikines are peptide mimetics of cytokines that are smaller in molecular size than, and structurally unrelated to, the natural cytokines they emulate. Medikine's lead candidate, mdk-703, is currently in a phase 1 clinical trial in healthy volunteers. Ronald W. Barrett has been the CEO of the company since 2016.

Open Monoclonal Technology, Inc. engages in the genetic engineering of animals for discovery of human therapeutic antibodies. The firm’s transgenic animal platforms include OmniRat, industry’s first human monoclonal antibody technology based on rats; OmniMouse, a transgenic mouse that complements OmniRat and expands epitope coverage and; OmniFlic, the first engineered rat with a fixed light chain for development of bispecific, fully human antibodies. The company was founded in by Roland Buelow 2007 and is headquartered in San Diego, CA.

Medikine, Inc. is a privately held biopharmaceutical company located in an undisclosed location. The American company's mission is to transform the discovery of oncology, autoimmune disorder, and infectious disease therapeutics by employing a versatile drug discovery platform that generates modular "peptikines." These peptikines are peptide mimetics of cytokines that are smaller in molecular size than, and structurally unrelated to, the natural cytokines they emulate. Medikine's lead candidate, mdk-703, is currently in a phase 1 clinical trial in healthy volunteers. Ronald W. Barrett has been the CEO of the company since 2016.

Open Monoclonal Technology, Inc. engages in the genetic engineering of animals for discovery of human therapeutic antibodies. The firm’s transgenic animal platforms include OmniRat, industry’s first human monoclonal antibody technology based on rats; OmniMouse, a transgenic mouse that complements OmniRat and expands epitope coverage and; OmniFlic, the first engineered rat with a fixed light chain for development of bispecific, fully human antibodies. The company was founded in by Roland Buelow 2007 and is headquartered in San Diego, CA.